StockData
Latigo Biotherapeutics, Inc. logo

Latigo Biotherapeutics, Inc. (LTGO) stock

LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026
$13.76+1.16 (+9.21%)

Close on Nov 17, 2026Market cap $912.28MP/E –Yield 0.00%

Latigo Biotherapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$17.50M–
Q2 FY2026Jun 30, 2026$21.23M–
Q3 FY2025Sep 30, 2025$22.10M–
Q2 FY2025Jun 30, 2025$22.92M–

More Latigo Biotherapeutics figures

See a number that looks wrong?